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Abstract The RAS-MAPKinase pathway is a signal
transduction cascade which has been studied extensively
during the last decades for its role in human oncogenesis.
Activation of this cascade is controlled by cycling of the
RAS protein between an inactive and an active state and by
phosphorylation of downstream proteins. The signalling
cascade regulates cell proliferation, differentiation and
survival. Disturbed RAS signalling in malignancies is
caused by acquired somatic mutations in RAS genes or
other components of this pathway. Recently, germline
mutations in genes coding for different components of the
RAS signalling cascade have been recognized as the cause
of several phenotypically overlapping disorders, recently
referred to as the neuro-cardio-facial-cutaneous syndromes.
Neurofibromatosis type 1, Noonan, LEOPARD, Costello
and cardiofaciocutaneous syndromes all present with
variable degrees of psychomotor delay, congenital heart
defects, facial dysmorphism, short stature, skin abnormal-
ities and a predisposition for malignancy. These findings
point to important roles for this evolutionary conserved
pathway in oncogenesis, development, cognition and
growth. Conclusion: it has become obvious in recent years
that the neuro-cardio-facial-cutaneous syndromes all share a
common genetic and pathophysiologic basis. Dysregulation
of the RAS-MAPKinase pathway is caused by germline
mutations in genes involved in this pathway. Undoubtedly
more genes causing related syndromes will be discovered in
the near future since there are still a substantial number of
genes in the pathway that are not yet associated with a
known syndrome.
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ERAS Embryonic stem cell-expressed rat sarcoma
viral oncogene homologue
ERK Extracellular signal-regulated kinase
GAP GTP-ase activating protein
GDP Guanosine diphosphate
GEF Guanosine nucleotide exchange factor
GTP Guanosine triphosphate
HRAS v-Harvey rat sarcoma viral oncogene
homologue
JMML Juvenile myelomonocytic leukaemia
KRAS Kirsten rat sarcoma viral oncogene
homologue
MAPK Mitogen activated protein kinase
MEK1 MAPK kinase/ERK kinase 1
MEK2 MAPK kinase/ERK kinase 2




NF1 Neurofibromatosis type 1
NRAS Neuroblastoma rat sarcoma viral oncogene
homologue
PTPN11 Protein-tyrosine phosphatase, nonreceptor-type
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Human genes and proteins are written in capital letters; murine genes
and proteins in small letters. Genes are written in italic, proteins are
written straight.
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RAF Murine sarcoma viral oncogene homologue
RAS Rat sarcoma viral oncogene homologue
SHP-2 Src homology protein 2
SOS1 Son of sevenless, drosophila, homologue 1
Introduction
The “neuro-cardio-facial-cutaneous (NCFC) syndromes” is a
term that was recently introduced to group neurofibroma-
tosis type 1 (NF1), LEOPARD syndrome, Noonan syn-
drome, Costello syndrome and cardio-facio-cutaneous
(CFC) syndrome [3]. These disorders all share a variable
degree of mental retardation, cardiac defects (often pulmo-
nary valve stenosis or hypertrophic cardiomyopathy), facial
dysmorphism, short stature, macrocephaly and skin abnor-
malities. Moreover, patients with these disorders all have an
increased risk for malignancy, except for CFC-syndrome
patients. In recent years, a common genetic and pathophys-
iologic basis for these phenotypically overlapping syn-
dromes has become obvious. The NCFC syndromes result
from germline mutations in genes of the evolutionary
conserved RAS-MAPKinase pathway. This signal transduc-
tion pathway plays a role in growth factor signalling and is a
well known factor in oncogenesis. It was already known for
some time that inactivating mutations in theNF1 gene, coding
for a negative regulator of RAS-signalling, are responsible for
neurofibromatosis type 1 (Von Recklinghausen’s disease)
[31], and that heterozygous missense mutations in PTPN11,
coding for SHP2, which positively modulates RAS signal-
ling, are found in 50% of Noonan syndrome patients [47] and
in most LEOPARD syndrome patients [11, 33]. In 2005, de
novo heterozygous missense mutations in HRAS were found
to be responsible for Costello syndrome [1, 14, 17, 26].
Somewhat later KRAS mutations were discovered in less than
2% of PTPN11-negative Noonan patients [6, 43, 54] and
recently mutations in the GEF SOS1 have been reported to
account for approximately 20% of PTPN11-negative Noonan
syndrome patients [40, 49]. Finally, in CFC syndrome,
mutations in KRAS, as well as BRAF, MEK1 and MEK2
were found [38, 41]. BRAF, MEK1 and MEK2 genes code for
proteins in the pathway located downstream of the RAS
proteins. The scope of this review is to describe the
similarities and dissimilarities of the clinical and molecular
aspects of these syndromes. An overview of the most typical
features of the NCFC syndromes is given in Table 1 and an
overview of the RAS-MAPK pathway and associated
syndromes is given in Fig. 1. In Fig. 2 pictures of typical
face of patients with Costello, Noonan and cardio-
faciocutaneous syndromes and skin abnormalities in patients
with neurofibromatosis type 1 and LEOPARD syndrome are
shown.
The RAS-MAPK pathway
RAS genes were first identified as homologues of rodent
sarcoma viruses. During the 1960s and 1970s a great deal
of research focused on retroviruses that caused tumours in
rodents. The goal of this research was to find similar
viruses inducing oncogenesis in humans, but this quest
turned out to be not very fruitful. However, in 1982 new
human DNA sequences homologous to the transforming
oncogenes of the v-Harvey (HRAS) and Kirsten rat sarcoma
virus (KRAS) were identified that caused oncogenic
transformation of mouse fibroblast cells [10]. These DNA
sequences were derived from a human bladder cancer and a
human lung cancer cell line, respectively. The findings
showed that RAS genes could act as oncogenes in human
cancer. It seemed that the amino acid substitution of glycine
12 of the RAS protein was responsible for the transforming
ability of this mutant RAS. Later on, two other family
members, NRAS (neuroblastoma RAS viral oncogene
homologue) and ERAS (Embryonic stem cell- expressed
RAS), were discovered.
RAS proteins are guanosine nucleotide-bound proteins
which cycle between an active GTP-bound and an inactive
GDP-bound conformation (Fig. 1). They are key molecules
in an evolutionary conserved intracellular signal transduc-
tion pathway, called the RAS-MAPK (mitogen activated
protein kinase) pathway. Mitogen activated protein (MAP)
kinases are proteins that phosphorylate (activate) other
proteins as a response to extracellular stimuli (mitogens)
and regulate various cellular activities, such as gene
expression, mitosis, differentiation, and cell survival/
apoptosis (programmed cell death). In the MAPK pathway
we find three kinases which sequentially activate each other
by phosphorylation of serine/threonine residues. Although
several MAPK pathways are known, only the extracellular
signal-regulated kinase (ERK) pathway will be discussed
here. This pathway is activated by binding of a growth
factor (“mitogen”) to a specific receptor (tyrosine kinase
type receptor). This causes dimerization of two receptor
molecules and activation of their kinase function. Different
intracellular proteins (adapter proteins) can bind to the
intracytoplasmic portion of these receptors and will activate
guanosine nucleotide exchange factors (GEFs) like SOS1.
These GEFs then activate membrane-bound RAS by
catalyzing exchange of GDP bound to RAS for GTP.
RAS-GTP can activate several different signalling mole-
cules of which RAF (MAPKKK=MAPkinasekinasekinase)
is the most important for this review. Activated RAF-
proteins phosphorylate and activate MEK (MAPKK=
MAPkinasekinase), which in turn phosphorylates and
activates ERK (=MAPKinase). ERK has more than 70
known substrates, of which include nuclear transcription
factors and signalling proteins. The result of signalling
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through this pathway is a change in the pattern of gene
expression which may cause cell proliferation, promote cell
survival or control cell differentiation. Signalling through
this cascade is terminated when GTP is hydrolyzed to GDP
by GTP-ase activating proteins (GAPs), like neurofibromin,
the protein product of NF1, or p120 GAP (mutated in
capillary malformation-arteriovenous malformation syn-
drome [13]). RAS-MAPK signalling was reviewed recently
[27] as well as RAS GDP-GTP cycling [12, 50]. An
overview of the RAS-MAPK pathway and associated
syndromes is given in Fig. 1.
RAS genes are proto-oncogenes which are mutated in
about 30% of human cancers, most frequently in adeno-
carcinomas of the pancreas, the colon and the lung, in
thyroid cancer and in myeloid leukaemia. RAS proteins in
cancer cells are frequently mutated at amino acids G12,
G13 and Q61. These mutations impair the GTP-hydrolysis
of RAS proteins which results in the accumulation of active
GTP-bound RAS and constant activation of downstream
proteins of the RAS-MAPK pathway [4]. This leads to
continuous proliferation of cells even in the absence of
growth factors. The protein immediately downstream of
RAS—RAF—is also a proto-oncogene. It has three iso-
forms of which BRAF is the most effective in activation of
the MAPK pathway. The gene coding for BRAF is mutated
in 7% of human cancers, most frequently malignant
melanoma, thyroid, colon and ovarian carcinomas [15].
Neurofibromatosis type 1 (OMIM 162200)
Neurofibromatis type 1 (NF1) is an autosomal dominant
condition characterized by pigmentation abnormalities of
the skin (café-au-lait macules, freckling in armpits and
groins) (Fig. 2a), Lisch nodules in the iris, and learning and
behavioural problems. There is a predisposition for the
development of tumours of the peripheral nerves such as
benign neurofibromas and malignant peripheral nerve sheet
tumours (MPNST). Rhabdomyosarcoma occurs at an
increased frequency in children with NF1. In rare situations
juvenile myelomonocytic leukaemia (JMML), a myelopro-
liferative disorder with a severe and often lethal course, is
observed. The NF1 protein (neurofibromin) (Fig. 1) is a
large protein with multiple functional domains. One
important domain is the GAP related domain which



































































































PS pulmonary valve stenosis, HCM hypertrophic cardiomyopathy, ASD atrium septum defect, MPNST malignant peripheral nerve sheet tumour,
JMML juvenile myelomonocytic leukaemia
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regulates RAS by stimulation of its conversion to the
inactive GDP-bound form. NF1 mutations disturb this GAP
activity of the protein resulting in more active RAS and
increased signalling through the RAS-MAPK pathway.
NF1 related tumours originate as a result of an acquired
inactivation of the only normal NF1 copy in an NF1 patient
(Knudsons second hit), and therefore the NF1 gene is a
tumour suppressor gene [31, 35, 36]. Somatic NRAS or
Fig. 2 Photographs of patients
with different NCFC syndromes.
a Typical café-au-lait macules in
a patient with neurofibromatosis
type 1. b Costello syndrome
patient with HRAS mutation.
c Noonan syndrome patient with
PTPN11 mutation. d Noonan
syndrome patient with SOS1
mutation. Note the skin abnor-
malities, the absence of
eyebrows and the sparse eye-
lashes. e Lentigines in
LEOPARD syndrome patient.
f Cardiofaciocutaneous
syndrome patient with BRAF
mutation
Fig. 1 Overview of the RAS-
MAPK pathway and associated
NCFC syndromes. Binding of a
growth factor to a receptor
tyrosine kinase (RTK) activates
RAS proteins by the action of
GEFs such as SOS which cata-
lyze guanosine nucleotide ex-
change. RAS-GTP activates
RAF and downstream effectors.
Signalling is terminated when
RAS-GTP is hydrolyzed to
RAS-GDP either by the action
of GAPs neurofibromin or p120
GAP. Responsible genes for
NF1, Noonan, LEOPARD,
Costello and CFC syndrome are
indicated
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KRAS mutations are responsible for approximately 25% of
sporadic cases of JMML [24], while in NF1 patients loss of
the normal copy of the NF1 gene is found [44]. Some NF1
patients also have features of Noonan syndrome and
“neurofibromatosis-Noonan syndrome” has been described
as a separate entity [9], but NF1 gene mutations represent
the major molecular event underlying neurofibromatosis-
Noonan syndrome [9].
Costello syndrome (OMIM 218040)
Costello syndrome, first described by Costello in 1971 and
1977 [7, 8], is a sporadic (non-familial), occurring disorder
characterized by a high birth weight, neonatal feeding
problems with subsequent failure to thrive and postnatal
growth retardation, redundant skin of the neck, palms and
soles, mental retardation, characteristic coarse facial fea-
tures, relative macrocephaly, cardiac abnormalities and
tumour predisposition. Typical facial features in Costello
syndrome (Fig. 2b) are a wide forehead, epicanthal folds,
depressed nasal bridge, low-set, posteriorly rotated ears
with thick lobes, full cheeks and thick lips. Hair is soft,
curly and sparsely implanted. Palmar and plantar creases
are deep. Benign papillomata in the peri-oral and peri-anal
region are a distinct feature. Cardiac defects are found in
63% of patients and include structural heart malformations,
most frequently pulmonary valve stenosis, hypertrophic
cardiomyopathy and rhythm disturbances, especially atrial
tachycardia [34]. Tumour risk in Costello syndrome is
estimated to vary from 11% [26] to 17% [18]. The most
common tumour observed is rhabdomyosarcoma, followed
by neuroblastoma and bladder carcinoma [16]. Mental
retardation is mild to moderate with IQ ranging from 25
to 85 [21].
In 2006, Aoki et al. identified missense mutations in
codons 12 and 13 of the HRAS gene in 12 individuals with
Costello syndrome [1]. The mutations were not present in
the parents and occurred “de novo”. This study was the first
report of germline RAS mutations as a cause of human
disease. Surprisingly, these HRAS heterozygous germline
mutations affect the same amino acid residues that are
mutated in cancer. Later reports confirmed the presence of
HRAS codon 12 and 13 mutations in 85–90% of Costello
syndrome patients with G12S being the most prevalent
mutation and G12A the second most prevalent [14, 17, 26].
One report described somatic mosaicism for an HRAS
codon 12 mutation [19]. As mentioned before, these
mutations derange RAS GTP-ase activity and cause
activation of the RAS MAPK pathway. Up until now only
two patients have been reported with HRAS mutations not
affecting aminoacids 12 or 13 of the protein: HRAS K117R
[26] and HRAS A146T [52]. These two mutations have
never been described in malignancies.
Noonan syndrome (OMIM 163950)
Noonan syndrome is an autosomal dominant disorder
which occurs with a frequency of 1/1000–1/2500 live
births. Patients have a short stature and specific facial
features (Fig. 2c) such as hypertelorism, ptosis, epicanthal
folds, low implanted and posteriorly rotated ears and clear
blue irises. The neck is broad and often webbed. Congenital
heart defects are found in 50–80%. Most frequent defects
are pulmonary valve stenosis (20–50%) and hypertrophic
cardiomyopathy (20–30%), but also ASD, VSD and
Fallot’s tetralogy can be found. Less frequent findings are
cryptorchidism in boys and bleeding diathesis with easy
bruising and increased risk of bleeding when undergoing
surgery. Developmental delay is present in 15–35% of
patients and is rather mild. Patients are at risk for
development of JMML and rhabdomyosarcoma.
Noonan syndrome has been mapped to a locus on
chromosome 12q24.1 by linkage analysis studies [5, 22,
32], and subsequently germline mutations in the PTPN11
gene have been found to account for approximately 50% of
Noonan syndrome patients [47]. PTPN11 is a non-receptor
protein tyrosine phosphatase encoding the SHP-2 protein
which relays signals from activated receptor complexes to
downstream signalling molecules, like RAS. PTPN11
mutations occurring in Noonan syndrome are almost
always missense mutations and most are gain-of-function
mutations. This results in an enhanced phosphatase activity
and activation of the RAS-MAPK pathway [46]. Specific
germline PTPN11 mutations are found in Noonan syn-
drome patients with JMML. Acquired PTPN11 mutations,
exhibiting stronger activation of SHP-2, were found in
about 35% of non-syndromic JMMLs [28, 48].
Genotype-phenotype correlation of Noonan syndrome
patients with or without PTPN11 mutations was studied by
Zenker et al. in 57 unrelated patients [53]. PTPN11
mutations were significantly associated with the presence
of pulmonary valve stenosis, short stature, easy bruising
and thorax deformities. PTPN11-negative patients more
frequently showed cardiomyopathy and less typical facial
features. Most of these were patients without a family
history of Noonan syndrome, which has hampered further
genetic studies and the identification of additional Noonan
syndrome-associated genes for some time.
In 2006, KRAS mutations were found in less than 2% of
Noonan syndrome patients [6, 43, 54]. The phenotype
associated with KRAS mutations seems to have a broad
range varying from mild to severe Noonan syndrome with
features of CFC syndrome and Costello syndrome. One
patient with a JMML-like disorder has been described [43].
In contrast with HRAS mutations in Costello syndrome,
overlap between germline KRAS mutations in Noonan
syndrome and tumour specific mutations is more exception
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than rule. Only two mutations that were previously found in
cancer cells have been described in Noonan syndrome
patients (K5N, Q22R) [54]. In functional assays Noonan
syndrome associated-mutations have less pronounced stim-
ulating effects than known cancer associated mutations
[43]. One hypothesis to explain these findings is that KRAS
has important roles during embryogenesis, and therefore
strong activating KRAS mutations, like the ones found in
cancer, would not be tolerated in the germline and result in
embryonic lethality [29]. This idea is reflected by the fact
that mice with inactivated KRAS genes die in utero,
whereas inactivation of HRAS or NRAS genes is not lethal
in mice [23].
The quest for Noonan syndrome-associated genes very
recently revealed another new player in the field; mutations
in SOS1, an important GEF (activator of RAS proteins),
account for 10–20% of Noonan syndrome patients [40, 49].
Phenotypically these patients often present with ectodermal
abnormalities (dry scaly skin, absent eyebrows and eye-
lashes) (Fig. 2d), but development and growth are often
normal.
LEOPARD syndrome (OMIM 151100)
LEOPARD syndrome is an acronym which refers to the
combination of multiple Lentigines, ECG abnormalities,
Ocular hypertelorism, Pulmonary valve stenosis, Abnor-
malities of the genitalia, Retardation of growth and
sensorineural Deafness. It is inherited as an autosomal
dominant disorder. Most typical features are multiple
lentigines, a “Noonan-like” facial appearance and congen-
ital cardiac abnormalities. Apart from pulmonic stenosis,
also subvalvular aortic stenosis and progressive cardiomy-
opathy are found. Mental retardation is usually mild, if
present. Specific heterozygous missense mutations in
PTPN11 are found in these patients [11, 33].
Cardiofaciocutaneous syndrome (OMIM 115150)
Cardiofaciocutaneous (CFC) syndrome is a rare sporadic
(non-familial) occurring disorder. Previously, much debate
has arisen whether it is a separate condition or a severe
variant of Noonan syndrome. Mutation analysis however
did not reveal PTPN11 mutations in typical CFC syndrome,
which points to the distinct aetiology of the syndrome [25].
Affected individuals often present with polyhydramnios
during pregnancy and postnatal failure to thrive. Typical
facial findings (Fig. 2e) are a high forehead with bitemporal
constriction, downslanting palpebral fissures, a depressed
nasal bridge and posteriorly rotated ears with prominent
helices. Differential diagnosis with other NCFC syndromes
like Costello syndrome and severe Noonan syndrome is
mainly based on the typical ectodermal abnormalities: dry,
hyperkeratotic, scaly skin and sparse, curly and friable
scalp hair. Ulerythaema ophryogenes (absent eyebrows
with hyperkeratosis) is a distinct feature. At an older age
palmoplantar hyperkeratosis and lymphoedema may be
observed. Psychomotor delay in these patients is moderate
to severe. One or more cardiac abnormalities are found in
75% of individuals, with pulmonary valve stenosis in 45%,
atrial septum defect (ASD) in 22% and some form of
myocardial disease (most often hypertrophic cardiomyop-
athy) in 40% [39]. In contrast to the other NCFC
syndromes, CFC syndrome is believed to have no increased
malignancy risk. The observation however of acute lym-
phoblastoid leukaemia (ALL) in one patient with CFC
syndrome [38] raises questions about this matter, although
the possibility exists that this finding is due to a
coincidence. BRAF mutations (Fig. 1) are found in 40%
[38] to 78 [41]% of CFC patients. The most prevalent
mutation (Q257R) is in the cysteine-rich domain (in exon
6) and another cluster of mutations is located in the protein
kinase domain (mutations in exons 11, 12, 14 and 15). Most
of the CFC associated-BRAF mutations are not found in
cancer. Mutations in the proteins immediately downstream
in the pathway, MEK1 and MEK2, have also been found in
CFC individuals [41, 37]. KRAS mutations have been
reported in four individuals with a clinical diagnosis of
CFC syndrome [38, 43]. Phenotypically these patients had
less typical skin abnormalities. Since evidence is emerging
that Noonan syndrome is caused by mutations in KRAS and
upstream signalling molecules, while CFC syndrome is
caused by mutant downstream molecules of RAS, it seems
reasonable to classify all individuals with germline KRAS
mutations as having Noonan syndrome [42].
Conclusions
Recently, germline mutations in genes of the RAS-MAPK
pathway have been discovered as the cause of the NCFC
syndromes. Common features in these disorders are
variable degrees of learning difficulties, facial dysmor-
phism, short stature, and tumour predisposition pointing to
the importance of RAS-MAPK signalling in oncogenesis as
well as in cognition, development and postnatal growth.
Studies in other species show that these different functions
of the RAS signalling pathway are evolutionary conserved,
e.g. learning and memory are affected in mice [45] as well
as in drosophila models [20] for NF1. NF1 also seems to be
important for growth in Drosophila [51]. Inactivation of Nf1
in the murine central nervous system results in optic glioma
formation [55]. Myeloproliferative disease develops in mice
with inactivation of Nf1 in haematopoietic cells [30], as
well as in mice heterozygous for the activating D61G
PTPN11 mutation [2].
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Still, a lot of questions do remain. How mutations in
different components of the same signalling pathway result
in different yet overlapping phenotypes is not fully
understood. There are still many (especially Noonan
syndrome) patients in whom no mutation in any of the
known genes is found. It is very likely that other genes of
the same pathway are mutated in these patients and in other
NCFC syndromes. Undoubtedly more data on these issues
will be discovered in the near future.
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